Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Metagenomi Therapeutics (MGX) Accumulated Depreciation & Amortization (2023 - 2025)

Metagenomi (MGX) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 41.64% to $16.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.0 million through Dec 2025, up 41.64% year-over-year, with the annual reading at $16.0 million for FY2025, 41.64% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $16.0 million at Metagenomi, up from $11.3 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $16.0 million in Q4 2025, with the low at $6.4 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $11.2 million, with a median of $11.3 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 75.15% in 2024, then soared 41.64% in 2025.
  • Over 3 years, Accumulated Depreciation & Amortization stood at $6.4 million in 2023, then surged by 75.15% to $11.3 million in 2024, then skyrocketed by 41.64% to $16.0 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $16.0 million, $11.3 million, and $6.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.